LMAT icon

LeMaitre Vascular

83.00 USD
-0.28
0.34%
At close May 14, 4:00 PM EDT
After hours
83.00
+0.00
0.00%
1 day
-0.34%
5 days
1.16%
1 month
-0.93%
3 months
-15.86%
6 months
-18.24%
Year to date
-9.26%
1 year
6.36%
5 years
238.50%
10 years
730.00%
 

About: LeMaitre Vascular Inc manufactures and distributes medical devices for the treatment of peripheral vascular disease. Its products are used during open vascular surgery and address several anatomical areas, such as the carotid, lower extremities, upper extremities, and aorta. The firm's lower extremities product line contributes towards the proportion of revenue, followed by the carotid product line. LeMaitre's surgical devices include angioscopes, balloon catheters, carotid shunts, phlebectomy devices, vascular grafts, vascular patches and vessel closure systems.It has a single operating segment engaged in the development, manufacturing, and marketing of medical devices and implants, as well as the processing and cryopreservation of human tissues for implantation in patients.

Employees: 664

0
Funds holding %
of 7,425 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

75% more first-time investments, than exits

New positions opened: 42 | Existing positions closed: 24

27% more repeat investments, than reductions

Existing positions increased: 121 | Existing positions reduced: 95

24% more call options, than puts

Call options by funds: $332K | Put options by funds: $267K

5% more funds holding

Funds holding: 288 [Q3] → 303 (+15) [Q4]

1.26% more ownership

Funds ownership: 92.92% [Q3] → 94.18% (+1.26%) [Q4]

1% more capital invested

Capital invested by funds: $1.94B [Q3] → $1.95B (+$11.6M) [Q4]

0% more funds holding in top 10

Funds holding in top 10: 4 [Q3] → 4 (+0) [Q4]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$110
33%
upside
Avg. target
$110
33%
upside
High target
$110
33%
upside

2 analyst ratings

positive
100%
neutral
0%
negative
0%
Lake Street
Brooks O'Neil
27% 1-year accuracy
4 / 15 met price target
33%upside
$110
Buy
Maintained
28 Feb 2025
Citizens Capital Markets
Daniel Stauder
45% 1-year accuracy
5 / 11 met price target
33%upside
$110
Buy
Maintained
28 Feb 2025

Financial journalist opinion

Based on 4 articles about LMAT published over the past 30 days

Neutral
GlobeNewsWire
1 week ago
LeMaitre to Present at the Bank of America Securities 2025 Healthcare Conference
BURLINGTON, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that David Roberts, President, will present at the Bank of America Securities 2025 Healthcare Conference on Tuesday, May 13, 2024, at 5:00 PM PDT at the Encore at the Wynn Hotel in Las Vegas, NV.
LeMaitre to Present at the Bank of America Securities 2025 Healthcare Conference
Neutral
Seeking Alpha
1 week ago
LeMaitre Vascular, Inc. (LMAT) Q1 2025 Earnings Call Transcript
LeMaitre Vascular, Inc. (LMAT) Q1 2025 Earnings Call Transcript
LeMaitre Vascular, Inc. (LMAT) Q1 2025 Earnings Call Transcript
Negative
Zacks Investment Research
1 week ago
LeMaitre Vascular (LMAT) Lags Q1 Earnings Estimates
LeMaitre Vascular (LMAT) came out with quarterly earnings of $0.48 per share, missing the Zacks Consensus Estimate of $0.50 per share. This compares to earnings of $0.44 per share a year ago.
LeMaitre Vascular (LMAT) Lags Q1 Earnings Estimates
Neutral
GlobeNewsWire
1 week ago
LeMaitre Q1 2025 Financial Results
BURLINGTON, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq: LMAT), a provider of vascular devices, implants, and services, today reported Q1 2025 results, announced a quarterly dividend of $0.20/share, and provided guidance.
LeMaitre Q1 2025 Financial Results
Positive
Zacks Investment Research
1 month ago
LeMaitre (LMAT) Soars 7.7%: Is Further Upside Left in the Stock?
LeMaitre (LMAT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
LeMaitre (LMAT) Soars 7.7%: Is Further Upside Left in the Stock?
Neutral
GlobeNewsWire
1 month ago
LeMaitre Will Announce First Quarter 2025 Earnings Results May 1, 2025
BURLINGTON, Mass., April 07, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its first quarter 2025 financial results on Thursday, May 1, 2025, after the market close. The company has scheduled a conference call for 5:00 PM EDT the same day to discuss the results, business highlights, and company outlook.
LeMaitre Will Announce First Quarter 2025 Earnings Results May 1, 2025
Neutral
Zacks Investment Research
1 month ago
4 Low-Beta Healthcare Stocks to Beat Trump's Tariff Blues
Healthcare stocks like GLID, COR, FMS and LMAT are a safe bet during times of market volatility.
4 Low-Beta Healthcare Stocks to Beat Trump's Tariff Blues
Neutral
Seeking Alpha
1 month ago
Small-Cap Dividend Stocks: Hidden Gems Or High-Risk Plays? - Top U.S. And Canadian Ones
Over the past decade, the iShares S&P/TSX SmallCap Index ETF has underperformed broader markets due to its heavy exposure to resource-heavy sectors like energy and materials. Acme's dividend track record spans over 15 years, with a modest but steady payout. Debt levels remain low, and management is highly focused on operational efficiency. With regulated pricing, recurring revenue, and defensive characteristics, York Water is a favorite for income-seekers looking for small-cap stability.
Small-Cap Dividend Stocks: Hidden Gems Or High-Risk Plays? - Top U.S. And Canadian Ones
Neutral
GlobeNewsWire
1 month ago
LeMaitre to Present at the 24th Annual Needham Virtual Healthcare Conference
BURLINGTON, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will present at the 24th Annual Needham Virtual Healthcare Conference on Tuesday, April 8, 2025, at 3:45 PM EDT.
LeMaitre to Present at the 24th Annual Needham Virtual Healthcare Conference
Negative
Seeking Alpha
1 month ago
Stocks Falling On Earnings - What To Do? February Dividend Income Report
Alimentation Couche-Tard has several growth vectors in place with a clear 5-year plan, including organic growth and growth by acquisition. Starting in March, I will increase my Smith Manoeuvre contribution from $500 to $750 monthly. CCL Industries reported another good quarter with revenue up 9% and EPS up 5%.
Stocks Falling On Earnings - What To Do? February Dividend Income Report
Charts implemented using Lightweight Charts™